Search
Idursulfase
go.drugbank.com/drugs/DB01271ApprovedInvestigationalThe enzyme contains eight asparagine-linked glycosylation sites occupied by complex oligosaccharide structures. … Idursulfase is produced by recombinant DNA technology in a human cell line.
Phenmetrazine
go.drugbank.com/drugs/DB00830ApprovedIllicitA sympathomimetic drug used primarily as an appetite depressant. Its actions and mechanisms are similar to dextroamphetamine.
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigational[L41524] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis. … in MS therapy.
Trifarotene
go.drugbank.com/drugs/DB12808ApprovedInvestigationalTrifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019. … ] Trifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects as compared
Categories: Retinoids for Topical Use in AcneGefapixant
go.drugbank.com/drugs/DB15097ApprovedIt received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications. … [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601]
Milnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalimportant role in the mitigation of pain signals in the descending inhibitory pain pathways in the brain and spinal cord [A175759, A175843, A175846]. … Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment
Catumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122]. … Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency.
Remoxipride
go.drugbank.com/drugs/DB00409ApprovedWithdrawn[A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512] … Remoxipride is an atypical antipsychotic agent that is specific for dopamine D<sub>2</sub> receptors.
Difelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigationalDifelikefalin (CR845) is an agonist of kappa opioid receptors (KORs) useful in the treatment of pruritus secondary to chronic kidney disease. KORs were first associated with itching in 1984. … [A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes
Lecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[A253947,A253957] In clinical trials, it significantly reduced brain Aβ plaques compared to placebo. … [A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.